Loading viewer...
earnings
Format: PDF earnings
Halozyme Therapeutics reported Q4 and FY 2023 financial results, highlighting its industry-leading ENHANZE® drug delivery platform with 7 approved partnered products in 100+ countries and approximately 800,000 patients treated. The company provides guidance for 2024 and a longer-term outlook through 2028, emphasizing platform expansion and development of a high-volume auto-injector.
conference
20 Pages
earnings
42 Pages
Vedanta Limited
JDE Peet's Half-Year Results 2021
earningsearnings
31 Pages
JDE Peet's N.V.
The Hartford Q2 2023 Earnings Results & Financial Performance
earningsearnings
19 Pages
The Hartford Financial Services Group, Inc.